argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?

Argenx's top and bottom lines are growing robustly. The company expects to report multiple pivotal clinical results through the second half of 2027.

The Motley Fool • Sep 2, 2026

BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery

TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation led by argenx's own scientists, the agreement represents a significant milestone in BenchSci's expansion across European biopharma. U.

Business Wire • Sep 2, 2026

argenx to Present at Upcoming Investor Conferences

September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September:

GlobeNewsWire • Sep 1, 2026

argenx Completes Acquisition of Forte Biosciences, Inc.

Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx's immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced the successful completion of the acquisition of Forte Biosciences, Inc. (“Forte”) (Nasdaq: FBRX). The acquisition expands argenx's portfolio of differentiated immunology medicines, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases.

GlobeNewsWire • Aug 27, 2026

Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story

Argenx recently announced Phase 3 results for Vyvgart Hytrulo in treating autoimmune myositis. While there was one disappointment with the clinical study, the results were positive overall.

The Motley Fool • Aug 26, 2026

These Analysts Boost Their Forecasts On Argenx

Argenx SE (NASDAQ:ARGX) on Monday disclosed positive topline results from its Phase 3 ALKIVIA study.

Benzinga • Aug 18, 2026

argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis Transcript

argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis Transcript

Seeking Alpha • Aug 18, 2026

ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up

argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.

Zacks Investment Research • Aug 18, 2026

Argenx says efgartigimod met main goal in myositis trial

Belgian-Dutch immunology company argenx ARGX.BR said its drug efgartigimod met the primary endpoint ​in a late-stage study treating adults ‌with autoimmune myositis, showing significant improvement in disease activity.

Reuters • Aug 17, 2026